Alterations in the expression of tumor necrosis factor-alpha in the uveitis with optic nerve inflammation
DOI:
https://doi.org/10.31288/oftalmolzh201651821Keywords:
uveitis with optic nerve inflammation, tumor necrosis factor-alphaAbstract
Purpose: To assess serum levels of tumor necrosis factor-alpha (TNF-?) in uveitis patients with optic nerve inflammation (ONI).
Materials and Methods: A retrospective evaluation of 132 patients who underwent examination and treatment for uveitis with ONI was performed. A commercially available enzyme-linked immunosorbent assay kit was used to measure serum TNF-? levels. Serum samples of 30 healthy donors were used as controls.
Results: Serum TNF-? levels in uveitis patients with ONI were 3.8 times higher compared to those in healthy controls (15.8 ± 1.02 pg/mL and 4.1 ± 1.52 pg/mL, respectively, p < 0.05). The highest increase in serum TNF-? levels compared to controls was seen in intermediate uveitis.
Conclusion: Serum TNF-? levels in active period of uveitis with ONI were found to be statistically significantly increased compared to those in controls. This finding provides the rationale for the use of anti-TNF-? agents for the treatment of uveitis with optic nerve inflammation.
References
1.Molins B, Mesquida M, Lee RW, et al. Regulatory T cell levels and cytokine production in active non-infectious uveitis: in-vitro effects of pharmacological treatment. Clin Exp Immunol. 2015 Mar;179(3):529-38 https://doi.org/10.1111/cei.12479
2.Santos Lacomba M, Marcos Mart?n C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001 Sep-Oct;33(5):251-5 https://doi.org/10.1159/000055677
3.Chang KC, Shieh B, Petrash JM. Aldose reductase mediates retinal microglia activation. Aldose reductase mediates retinal microglia activation. Biochem Biophys Res Commun. 2016 Apr 29;473(2):565-71 https://doi.org/10.1016/j.bbrc.2016.03.122
4.Yadav UC, Shoeb M, Srivastava SK, Ramana KV. Aldose reductase deficiency protects from autoimmune- and endotoxin-induced uveitis in mice. Invest Ophthalmol Vis Sci. 2011 Oct 17;52(11):8076-85 https://doi.org/10.1167/iovs.11-7830
5.Caspi RR. Understanding autoimmune uveitis through animal models. The Friedenwald Lecture. Invest Ophthalmol Vis Sci. 2011;52(3): 1872-9 https://doi.org/10.1167/iovs.10-6909
6.Trinh L, Brignole-Baudouin F, Pauly A, et al. Th1- and Th2-related chemokine and chemokine receptor expression on the ocular surface in endotoxin-induced uveitis. Mol Vis. 2008; 14: 2428-34
7.Turgut B, Gul FC, Dagli F, et al. Impact of ghrelin on vitreous cytokine levels in an experimental uveitis model. Drug Des Devel Ther. 2013 9;7:19-24 https://doi.org/10.2147/DDDT.S39453
8.Ortencio KP, Renzo R, Sobrinho B AA, et al. Effects of morphine on the expression of cytokines and inflammatory mediators in a rabbit model of endotoxin-induced experimental uveitis. Arq Bras Oftalmol. 2015 Nov-Dec;78(6):371-5 https://doi.org/10.5935/0004-2749.20150098
9.Nagata K, Maruyama K, Uno K, et al. Simultaneous analysis of multiple cytokines in the vitreous of patients with sarcoid uveitis. Invest Ophthalmol Vis Sci. 2012 Jun 20;53(7):3827-33 https://doi.org/10.1167/iovs.11-9244
10.Shibata M, Sato T, Taguchi M, et al. Analysis of Cytokines Related to Helper T and Regulatory T Cells in the Vitreous of Uveitis Patients. Nippon Ganka Gakkai Zasshi. 2015 Jun;119(6):395-401
11.Chen W, Zhao B, Jiang R, et al. Cytokine expression profile in aqueous humor and sera of patients with acute anterior uveitis. Curr Mol Med. 2015 ;15(6):543-9 https://doi.org/10.2174/1566524015666150731100012
12.Hern?ndez Garfella ML, Palomares Fort P, Rom?n Ivorra J, Cervera Taulet E. Aqueous Humor Levels of Different Interleukins 1-?, 2, 6 and 10, Tumor Necrosis Factor-? and Vascular Endothelial Growth Factor in Uveitis Treated with Adalimumab. J Ophthalmic Vis Res.2015 Jan-Mar;10(1):49-54 https://doi.org/10.4103/2008-322X.156110
13.Sijssens KM, Rijkers GT, Rothova A, et al. Cytokines, chemokines and soluble adhesion molecules in aqueous humor of children with uveitis. Exp Eye Res. 2007 Oct 22;85(4):443-9 https://doi.org/10.1016/j.exer.2007.06.011
14.El-Asrar AM, Struyf S, Kangave D, et al. Cytokine and CXC chemokine expression patterns in aqueous humor of patients with presumed tuberculous uveitis. Cytokine. 2012 Aug;59(2):377-81 https://doi.org/10.1016/j.cyto.2012.04.030
15.El-Asrar AM, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011 May;139(2):177-84 https://doi.org/10.1016/j.clim.2011.01.014
16.Lahmar I, Abou-Bacar A, Abdelrahman T, et al. Cytokine Profiles in Toxoplasmic and Viral Uveitis. J Infect Dis. 2009;199:1239-49 https://doi.org/10.1086/597478
17.Takase H, Futagami Y, Yoshida T, et al. Cytokine Profile in Aqueous Humor and Sera of Patients with Infectious or Noninfectious Uveitis. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1557-61 https://doi.org/10.1167/iovs.05-0836
18.Franks WA, Limb GA, Stanford MR, et al. Cytokines in human intraocular inflammation. Curr EyeRes. 1992; 11(Suppl):187-91 https://doi.org/10.3109/02713689208999531
19.Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121(4):437-40 https://doi.org/10.1001/archopht.121.4.437
20.Cordero-Coma M, Calleja S, Llorente M, et al. Serum cytokine profile in adalimumab-treated refractory uveitis patients: decreased IL-22 correlates with clinical responses. Ocul Immunol Inflamm. 2013 Jun;21(3):212-9 https://doi.org/10.3109/09273948.2013.770888
21.Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh?et's disease. Mediators Inflamm. 2002 Apr;11(2):87-93 https://doi.org/10.1080/09629350220131935
22.Mesquida M, Molins B, Llorens V, et al. Proinflammatory cytokines and C-reactive protein in uveitis associated with Behcet's disease [Electronic resource]. Mediators Inflamm. 2014. https://doi.org/10.1155/2014/396204
23.T?rkc? FM, ?ahin A, Cing? AK, et al. Serum omentin, resistin and tumour necrosis factor-? levels in Behcet patients with and without ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2015 Sep;253(9):1565-8 https://doi.org/10.1007/s00417-015-3016-0
24.Curnow SJ, Falciani F, Durrani OM, et al. Multiplex Bead Immunoassay Analysis of Aqueous Humor Reveals Distinct Cytokine Profiles In Uveitis. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4251-9 https://doi.org/10.1167/iovs.05-0444
25.Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-? therapy in uveitis. Surv Ophthalmol. 2015 Nov-Dec;60(6):575-89 https://doi.org/10.1016/j.survophthal.2015.06.004
26.Jaffe GL, Thorne JE, Scales D, et al. SAT0523 Adalimumab in Patients with Active, Non-Infectious Uveitis Requiring High-Dose Corticosteroids: the Visual-1 Trial. Ann Rheum Dis. 2015;74:849-50 https://doi.org/10.1136/annrheumdis-2015-eular.2799
27.Brooks M. FDA Clears Adalimumab (Humira) for Uveitis [Electronic resource] / M. Brooks // Medscape. - 2016.http://www.medscape.com/viewarticle/865654
28.Khovalyg NM, Fadeeva NI, Korenovskiy YuV. [Determination of matrix metalloproteinase type 9 in the plasma of premature neonates for the prognosis of perinatal damage to the CNS of premature neonates]. In: [Proceedings of the 8th International Congress on Health and Education in the 21st Century: Concepts of Diseases of Civilization]. Health and Education in the 21st Century Journal. 2007;9(4):334. Russian
29.Yamada H, Yoneda M, Inaguma S, et al. Infliximab counteracts tumor necrosis factor-?-enhanced induction of matrix metalloproteinases that degrade claudin and occludin in non-pigmented ciliary epithelium. Biochem Pharmacol. 2013 Jun 15;85(12):1770-82 https://doi.org/10.1016/j.bcp.2013.04.006
30.Panchenko NV, Samofalova MN, Friantseva MV. [Levels of matrix metalloproteinase type 9 in different outcomes of uveitis with optic nerve inflammation]. Oftalmologiia. Vostochnaia Evropa. 2016;6(2):210-6. Russian
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Н. В. Панченко, М. Н. Самофалова, Е. Н. Гончарь, Д. О. Приходько, Г. С. Арустамова, А. В. Литвищенко
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
